Meningococcal polysaccharide a, c, w135, y conjugate vaccine
- Drugs List
- Therapeutic Indications
- Dosage
- Administration
- Contraindications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
- Monograph
Presentation
Pre-filled syringe
One dose (0.5ml of reconstituted vaccine) contains:
Meningococcal group A polysaccharide 5micrograms
Meningococcal group C polysaccharide 5micrograms
Meningococcal group W135 polysaccharide 5micrograms
Meningococcal group Y polysaccharide 5micrograms
Conjugated to tetanus toxoid carrier protein.
Vial
One dose (0.5ml of reconstituted vaccine) contains:
Meningococcal group A polysaccharide 10micrograms
Meningococcal group C polysaccharide 10micrograms
Meningococcal group W135 polysaccharide 10micrograms
Meningococcal group Y polysaccharide 10micrograms
Conjugated to tetanus toxoid carrier protein.
Drugs List
Therapeutic Indications
Uses
Prophylaxis against meningococcal meningitis group A, C, W135 and Y
Active immunisation of individuals at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease.
For comprehensive information or advice on this product or the immunisation programme in the UK, the following website should be accessed.
https://www.gov.uk/government/organisations/public-health-england/series/immunisation-against-infectious-disease-the-green-book
Dosage
Adults
Single dose of 0.5ml.
Children
Pre-filled syringe
Children aged from 6 weeks to 6 months
Two doses of 0.5ml, with an interval of 2 months between doses.
Children aged 6 months to 18 years
Single dose of 0.5ml.
Vial
Children aged 12 months to 18 years
Single dose of 0.5ml.
Additional Dosage Information
If a toddler is at a particular risk of invasive meningococcal disease after exposure to Neisseria meningitidis groups W-135 or Y, consider administering a second vaccine dose after an interval of two months. The vaccine-elicited bactericidal response against groups W-135 and Y is higher after two doses compared to one.
A booster dose may be considered in individuals vaccinated at toddler age who remain exposed to meningococcal disease caused by Neisseria meningitidis groups A, C, W-135 or Y.
Administration
To be given by intramuscular injection into the deltoid. Individuals under 1 year of age may be administered into the anterolateral aspect of the thigh.
Contraindications
Children under 6 weeks
Severe febrile conditions
Precautions and Warnings
Children aged 6 weeks to 12 months
Immunosuppression
Breastfeeding
Coagulopathy
Hereditary complement deficiencies
Immunodeficiency syndromes
Pregnancy
Thrombocytopenia
Postpone immunisation if there is active or suspected infection
Advise ability to drive/operate machinery may be affected by side effects
Impaired response possible in immunocompromised patients
Not all available brands are licensed for all age groups
Protection against meningococci groups A, C, W135 and Y only
Vaccine may not be effective in 100% of patients
Do not mix with other vaccines in the same syringe
Do not use if solution is discoloured or particulates are apparent
Inject other vaccines at different sites
Record name and batch number of administered product
Resuscitation facilities must be immediately available
Establish full medical history and health status prior to vaccine
Remain alert to possible coincidental meningitis
Follow national immunisation guidelines
Syncope can occur before or following vaccination, especially in adolescents as a psychogenic response to the needle injection. Ensure procedures are in place to avoid injury from faints.
The vaccine should administered at least one month before an anti-tetanus toxoid containing vaccine, or co-administered at the same time.
Lower hSBA geometric mean titres (GMTs) against serogroup A have been observed following a single dose of the vaccine. This should be considered for individuals at high risk of MenA infection who received MenC-CRM vaccine in their first year of life.
Pregnancy and Lactation
Pregnancy
Use meningococcal A, C, W135 and Y conjugate vaccine with caution during pregnancy.
The manufacturer advises meningococcal vaccines may be used during pregnancy if the expected benefits outweigh the potential risks. At the time of writing there is limited published information regarding the use of meningococcal vaccines during pregnancy. Potential risks are unknown.
Lactation
Use meningococcal A, C, W135 and Y conjugate vaccine with caution during breastfeeding.
The manufacturer advises meningococcal vaccines may be used when breastfeeding if the advantages outweigh the potential risks. The presence of meningococcal vaccines in human breast milk and its effect on exposed infants is unknown.
Side Effects
Abdominal pain
Axillary pain
Chills
Crying
Decreased appetite
Diarrhoea
Dizziness
Drowsiness
Erythema at injection site
Fatigue
Fever
Gastro-intestinal symptoms
Haematoma (injection site)
Headache
Hypoaesthesia
Induration (injection site)
Insomnia
Irritability
Limb swelling
Local pain (injection site)
Localised areas of anaesthesia
Lymphadenopathy
Malaise
Myalgia
Nausea
Painful extremities
Pruritus
Rash
Sensation of warm and/or cold at injection site
Swelling (injection site)
Urticaria
Vomiting
Overdosage
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Further Information
Last Full Review Date: October 2021
Reference Sources
Summary of Product Characteristics: MenQuadfi solution for injection. Sanofi Pasteur. Revised September 2021.
Summary of Product Characteristics: Nimenrix powder and solvent for solution for injection in pre-filled syringe. Pfizer Limited. Revised October 2021.
Immunisation against infectious diseases: 'The Green Book', Department of Health.
Available at: https://www.gov.uk/government/organisations/public-health-england/series/immunisation-against-infectious-disease-the-green-book
Last accessed: 13 October 2021
NICE Evidence Services
Available at: www.nice.org.uk
Last accessed: 13 October 2021
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.